Journal of Clinical Lipidology

Article	Citations
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	285
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	150
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	108
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	100
Lipoprotein(a) concentrations across a global cross-sectional registry	98
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	92
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	85
Care of youth with lipid disorders: A brief provider survey	80
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	72
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	69
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	63
News from NLA	63
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	50
The impact of genetic testing on physician practice in specialized cardiovascular clinics	49
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	49
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	48
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	48
Inflammation and cardiometabolic disease in South Asians: The fire and fire tenders	47
Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	45
Exciting new developments in clinical lipidology: Updates from the Food and Drug Administration and the American Heart Association	45
Reanalysis of the impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials	44
Impact of Dose of Statins on LDL-C Goal Attainment in ASCVD Patients at a Tertiary Care Centre	41
Uncovering Multifactorial Genetics: A Case Report of Severe Familial Hypercholesterolemia with Suspected Oligogenic Factors in a Female Preschooler	40
Impact of Cardiovascular Prevention Clinic Attendance on Lipid Management in First-Degree Relatives of Patients with Premature Cardiovascular Disease	36
Obicetrapib CETP Inhibition Remodels HDL2 and Raises ApoM, S1P, ApoA1 Monomers, Boosting Plasma Xanthophyll and Carotenoid Levels	36

Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia	35
Quantifying the 'Lp(a) Floor': ApoB-Guided Identification of Lp(a)-Dominant Atherogenic Risk	35
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	34
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	34
Low-attenuation plaque-mediated NSTEMI in a patient with sarcoidosis and high Lp(a)	33
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	30
Predictive value of lipoprotein(a) in patients undergoing percutaneous coronary intervention with drug-eluting stent: A meta-analysis	29
Comparative efficacy of different statin intensities combined with ezetimibe on lipid profile improvement in patients with coronary heart disease: a network meta-analysis	26
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	25
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	25
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	25
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	24
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	24
News from the NLA	23
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	23
From the Editors: Update on Diagnosis and Treatment of Familial Hypercholesterolemia	22
Association of sleep duration and quality with small dense low-density lipoprotein cholesterol	21
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	20
Circumferential periorbital xanthelasma in Leonardo da Vinci’s Head of a Young Woman (1475-1480)	20
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	19
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	19
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	18
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	18
Table of Contents	18
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	18
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	17
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	17
Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography	17
Impact of an Alert System for Severe Hypercholesterolemia in a Large Healthcare System	16
Moving beyond clinical risk factors for diagnosis: The necessity of systematic Lp(a) measurement and familial hypercholesterolemia genetic testing	16
Remnant cholesterol and kidney disease progression in type 2 diabetes: A retrospective cohort study	16
*Opportunistic Cardiometabolic Risk Detection in Young Blood Donors	16
Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen	16
Early-pregnancy remnant cholesterol as a modifiable risk factor for gestational diabetes mellitus	15
Screening for familial hypercholesterolemia in the era of artificial intelligence: A contemporary narrative review	15
Data-Driven Decisions in Familial Chylomicronemia Syndrome: Outcomes from a CME Program on Emerging Therapeutic Strategies	15
†Accelerating Lipoprotein(a) Testing in Community Health Centers Through Quality Improvement and Education	15
Lipid-lowering therapy after finding high Lp(a)—adding ezetimibe or intensifying statin treatment?	15
Impact of Early Lipoprotein(a) Levels: A Case of Premature CVD in T1D and Elevated Lp(a)	15
Severe hypertriglyceridemia induced by everolimus in a lung transplant patient: Case report	15
Mystery Behind Presence of Peripheral Artery Disease in Familial Dysbetalipoproteinemia	15
Health outcomes and survival among patients with severe hypertriglyceridemia after acute pancreatitis	14
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	14
Lipoprotein(a) levels and common LPA gene variants in patients with chronic coronary syndrome: Genetic determinants and clinical associations	14
HDL and coronary artery disease	14
Response to: Comment on “Plasma-based low-grade inflammation and endothelial dysfunction explain a small but significant proportion of the association between the n-3 polyunsaturated fatty acids and c	13
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	13
Birth and First-Year Outcomes in Infants of Mothers with Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease In the US: A Retrospective Cohort Study	13
Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-con	13
Disruption of HDL antioxidant properties in children and adolescents with obesity	13

Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	13
Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia	13
Predictive value of LDL/HDL cholesterol ratio for new-onset stroke in individuals with cardiovascular–kidney–metabolic syndrome stages 0 to 3: Evidence from the China Health and Retirement Longitudina	13
Country-specific prevalence and clinical relevance of elevated Lp(a) as a risk enhancer in 2 Greek cohorts	13
The integrated triglyceride-glucose index and body shape indices for improvements in myocardial infarction risk prediction: findings from the Tehran Lipid and Glucose Study	13
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	13
Editorial Board	12
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	12
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	12
Familial hypercholesterolemia concealed by a protein-truncating variant of PCSK9	12
Effect of incorporating 1 avocado per day on lipoprotein particle concentrations compared to habitual intake in adults with abdominal obesity: An ancillary study of the Habitual Diet and Avocado Trial	12
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	12
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	11
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	11
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	11
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	11
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease	11
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	11
Enzyme replacement therapy in cholesteryl ester storage disease: A case report on lysosomal acid lipase deficiency management	11
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	11
Implementation strategies to optimize the use of nonstatin add-on lipid-lowering therapies in individuals with dyslipidemia: A systematic review	11
Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	11
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	11
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	11
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	11
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	11
Novel APOB variant causes familial hypercholesterolemia in multiple unrelated families	10
The 2025 AACE Dyslipidemia Guidelines – Cost concerns over evidence and missing the target?	10
Corrigendum to “Association between the cardiometabolic index and mortality risk in US adults: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018” [Journal of Clinical L	10
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	10
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	10
Lipoprotein(a) and TAVR outcomes: Methodological challenges and clinical implications	10
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	10
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	9
Clinical Translation of Gene and Genome Editing Therapies for Lipoprotein Disorders: A Systematic Review of Trial Design Targets and Safety	9
Comparative Effects of Tirzepatide and Other Glucose-Lowering Therapies on Fasting Lipid Parameters: A Random-Effects Network Meta-analysis of Randomized Controlled Trials	9
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	9
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	9
Real-World Comparative Effectiveness of Inclisiran Versus PCSK9 Monoclonal Antibodies in High-Risk Cardiovascular Patients on High-Intensity Statins	9
Response to the letter regarding “Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”	9
Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Calcium in Subclinical Coronary Atherosclerosis: A Systematic Review and Meta-Analysis	9
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	9
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	9
Community pharmacist impact of addressing statin use in patients with diabetes	9
Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program	9
Checking the Box vs. Staying the Course: Real-World Analysis of Statin Use Patterns	9
Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study Results	9
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	9
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	9
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	9
Multidimensional lipid phenotyping for stratification of residual cardiovascular risk: A focus on fatty acid balance	8
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	8
Enhancing lipoprotein(a) association studies: A complementary approach to principal component analysis	8
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	8
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	8
Effects of evinacumab on high-density lipoprotein function in patients with homozygous familial hypercholesterolemia	8
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	8
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	8
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	8
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	8
Inclisiran Versus Control Added to Maximally Tolerated Statin Therapy in Hyperlipidemia: Systematic Review and Bayesian Meta-Analysis	7
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	7
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	7
FocusHTG Registry: Early Results From Participants With Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (sHTG)	7
Mortality, cardiovascular, and hepatic decompensation outcomes of bempedoic acid in patients with cirrhosis: A multi-institutional study	7
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults: A randomized crossover trial	7
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	7
LDL-C Lowering with Inclisiran After Acute Coronary Syndrome: Analysis of Treatment Effect Heterogeneity in VICTORION-INCEPTION	7
Persistent Gaps in Management and Risk Factor Control Among Patients with Atherosclerotic Cardiovascular Disease: All of Us Research Program	7
Apolipoproteins and dyslipidemia in pediatric nephrotic syndrome in remission: Overestimation or underpowered evidence?	7
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	7
Bempedoic acid vs ezetimibe added to statin therapy: Cardiovascular outcomes in the real-world—The BEYOND-REAL Study	7
Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials	7
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	7
Evaluating elevated lipoprotein(a) clinical care impact in an academic health center	7
The Effects of Full-Fat and Low-Fat Fermented Dairy Foods on Markers of Cardiometabolic Health in Adults with Overweight or Obesity	7
Lipoprotein(a) plasma levels and coagulation biomarkers: Results from a comprehensive laboratory assessment in an angiographically controlled cardiovascular cohort	7
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	7
Plasma-based low-grade inflammation and endothelial dysfunction explain a small but significant proportion of the association between the n-3 polyunsaturated fatty acids and cardiovascular diseases: T	7
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	7

An Indian adapted Mediterranean diet: A feasibility study	7
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk	7
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	6
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	6
Table of Contents	6
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	6
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	6
Does apolipoprotein B matter in the care of familial hypercholesterolemia?	6
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	6
Characterization of Patients with Statin Intolerance in Routine Practice: Real-World Analysis Using NLP-Enhanced Veradigm Network EHR Linked Database	6
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	6
Lipoprotein(a) at the crossroads of inflammation and atherosclerosis in rheumatoid arthritis: A narrative review	6
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	6
Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	6
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	6
Impact of Dyslipidemia and Severe Hypercholesterolemia on Mortality, Intestinal Failure, and Resource Utilization in Acute Mesenteric Ischemia	6
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	6
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	6
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	6
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	6
Sex differences in inflammatory biomarkers during long-term evolocumab therapy	5
High lipoprotein(a) and stroke: Association with large artery and intracranial atherosclerosis—A retrospective study	5
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	5
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	5
Rethinking remnant reduction in hypertriglyceridemia: A functional perspective beyond the PROMINENT trial	5
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	5
Heterogeneous nature of severe hypertriglyceridemia in childhood	5
Lipoprotein(a) Testing After Acute Coronary Syndromes: A Missed Opportunity in Secondary Prevention	5
Trends in Lipoprotein(a) Testing Rates in Patients With ASCVD and Premature ASCVD: A Contemporary Analysis in a Large US Health Care System	5
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	5
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	5
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	5
From the Editors: New 2026 guideline for management of dyslipidemia	5
Cardiovascular disease and cholesterol lowering therapy in women and men with molecularly defined heterozygous familial hypercholesterolemia from Brazil	5
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	5
Population enrichment of ABCG5/ABCG8 variants in Qatar and genetic estimates of sitosterolemia burden	5
Associations of lipid-lowering drugs with cardiovascular-kidney-metabolic syndrome: A drug-target Mendelian randomization study	5
Lp(a) Ordering Patterns and Insights from a Large County Teaching Hospital System	5
Lipid-Lowering Therapy Intensity and Cardiovascular Outcomes in Patients with Familial Hypercholesterolemia Risk Phenotype and ASCVD	5
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	5
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	5
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	5
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	5
In memoriam: A tribute to Dr Scott M. Grundy	5
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	5
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	5
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	5
Omega-3 supplementation and Lp-PLA2: Attention to nonindependent comparisons in meta-analysis	5
Comparative Risk of Statin Exposure on Adverse Cardiovascular Outcomes in Solid Organ Transplant Recipients	5
Long-Term Safety and Effectiveness of Lomitapide in HoFH: 11 Years' Real-World Evidence from the Global LOWER Registry	5
Plasmapheresis for Familial Hyperlipidemia in 3 Pregnancies: A Case Series	5
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	5
From the editor: A compendium of lipidology progress	4
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	4
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	4
Healthcare Resource Utilization Among Patients Receiving Olezarsen Versus Placebo for Severe Hypertriglyceridemia in CORE/CORE2 Clinical Trials	4
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	4
Real-World Adherence, Persistence, and LDL-C Outcomes with Inclisiran Compared with PCSK9 Monoclonal Antibodies: Systematic Review	4
The Association of Elevated Lipoprotein(a) Level with Major Adverse Cardiovascular Events with Controlled LDL: A Retrospective Analysis	4
Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis	4
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	4
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	4
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	4
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	4
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	4
Genetic determinants of chylomicronemia in Taiwan: Predominance of LPL rare variants and APOA5 p.G185C	4
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	4
Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function	4
JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients	4
From the editor: Lipidology resurgent as the pandemic wanes	4
A Yellow Flag With No Red Numbers	4
Advancing Cardiovascular Health Initiative through Launch of Lipoprotein(a) Education & Screening (ACHILLES-QI)	4
Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials	4
Waist-to-Height Ratio Outperforms Body Mass Index in Predicting Systemic Inflammation: National Health and Nutrition Examination Survey 2015-2023	4
A novel VPS4A variant drives lipotoxicity underlying CIMDAG syndrome	4
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	4
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	4
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	4
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	4
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	4
Dedicated training in obesity management: A pathway to better physician practice	4
Impact of a Gamified Curriculum on Internal Medicine Resident Confidence and Knowledge of ASCVD Risk Management	4
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	4
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial	4
Lipoprotein(a): Mirroring Familial Hypercholesterolemia	4
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	4
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	4
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	3
Editorial Board	3
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	3
Prevalence and clinical characteristics of probable familial chylomicronaemia syndrome at a tertiary care center in Pakistan: Insights from a hospital-based screening study	3
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	3
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	3
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	3
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	3